Tukysa study in Korea after market release
Part of Cancer, Skin clinical trials.
This study watches how patients in Korea do while taking Tukysa for the first time. It helps doctors learn more about how the medicine works in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking Tukysa for the approved use.
- This is your first time being treated with Tukysa.
- You are 18 years old or older.
- You have signed a consent form to participate.
- You do not have any condition that makes Tukysa unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
This study looks at how patients with advanced breast cancer (HER2-positive type) respond to anti-HER2 drugs over time. Researchers in Kazakhstan are reviewing medical records to understand which treatments work best and help improve care for future patients.
This study follows patients in South Korea who have already received Kymriah (tisagenlecleucel) in a real-world setting. It aims to monitor their long-term health and any side effects over time.
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
This trial tests a new drug, TYK-00540, for people with solid tumors that have not responded to or cannot tolerate standard treatments. It also looks at specific types of breast and ovarian cancer.
This study follows people in Korea who are starting Talzenna® as decided by their doctor. It mainly collects safety and real-world use information, helping Pfizer monitor how the medicine works outside of tightly controlled trials.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.